Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 1.2%
Wed, 18 Sep 13:9

Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 1.2%Image source: StarLineArts/www.istockphoto.com

Glenmark Pharma share price has plunged 3% and is presently trading at Rs 1,658.5.

Meanwhile, the BSE HEALTHCARE index is at 43,780.0 (down 1.2%).

Among the top losers in the BSE HEALTHCARE index today are Abbott India (down 3.9%) and KIMS (down 3.5%).

POLY MEDICURE (up 3.1%) and GSK Pharma (up 0.9%) are among the top gainers today.

Over the last one year, Glenmark Pharma has moved up from Rs 850.8 to Rs 1,658.5, registering a gain of Rs 807.8 (up 94.9%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,508.7 to 43,780.0, registering a gain of 53.6% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 175.6%), SUVEN PHARMACEUTICALS (up 106.2%) and Lupin (up 96.2%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 83,172.9 (up 0.1%).

The top gainers among the BSE Sensex today are Bajaj Finance (up 3.7%) and Bajaj Finserv (up 2.3%). The most traded stocks in the BSE Sensex are SBI and Tata Steel.

In the meantime, NSE Nifty is at 25,386.7 (down 0.1%). TCS and HCl Tech. are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 67,596.8 to 83,172.9, registering a gain of 15,576.1 points (up 23.0%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.

For the year ended March 2024, Glenmark Pharma reported 1944.2% decrease in net profit to Rs -18,309 million compared to net loss of Rs 896 million during FY23. Revenue of the company grew 2.0% to Rs 118,131 million during FY24.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -30.6.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 1.2%". Click here!